BLAINJECTIONINJECTABLEPriority Review
Approved
Oct 2023
Lifecycle
Growth
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
5/8 — Partial
Priority Review
LOQTORZI (toripalimab-tpzi) by Coherus Biosciences Inc is programmed death receptor-1-directed antibody interactions [moa]. First approved in 2023.
Drug data last refreshed 16h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LOQTORZI (toripalimab-tpzi) is a PD-1 blocking monoclonal antibody approved in October 2023 for oncology indications. It works by binding to programmed death receptor-1 to enhance anti-tumor immune responses. The drug represents a checkpoint inhibitor approach to cancer treatment.
Growth
Early-stage growth product with modest competitive pressure (30%) suggests opportunity for commercial team expansion and field presence establishment.
Mechanism of Action
Programmed Death Receptor-1-directed Antibody Interactions
Pharmacologic Class:
Programmed Death Receptor-1 Blocking Antibody
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
TMV Vaccine Alone or With Toripalimab-tpzi for Recurrent Head and Neck Squamous Cell Carcinoma
Started Oct 2026
30 enrolled
Squamous Cell Carcinoma of Head and NeckSquamous Cell Carcinoma of Head and Neck (SCCHN)HNSCC+2 more
Why This Matters for Your Career
Worked on LOQTORZI at Coherus Biosciences Inc? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.